Fingolimod
Quick Facts
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Relapsing forms of multiple sclerosis — including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease | Patients ≥10 years | Monotherapy | FDA Approved |
Fingolimod is a sphingosine 1-phosphate (S1P) receptor modulator and was the first oral disease-modifying therapy approved for multiple sclerosis when the FDA cleared it in September 2010. The original approval covered adults; in May 2018, FDA expanded the indication to pediatric patients aged 10 years and older — the first MS therapy ever approved in this age group — based on the PARADIGMS trial. Approval rests on the Phase III FREEDOMS (vs placebo) and TRANSFORMS (vs intramuscular interferon beta-1a) trials in adults, both published in the New England Journal of Medicine in 2010.
Fingolimod is generally categorized as a moderate- to high-efficacy oral disease-modifying therapy for relapsing MS, alongside other S1P modulators (siponimod, ozanimod, ponesimod), oral fumarates (dimethyl fumarate, diroximel fumarate, monomethyl fumarate), and teriflunomide. Within the AAN treatment hierarchy, it is positioned for patients with breakthrough disease on platform injectable therapies or as a higher-efficacy first-line option in selected patients. The complex first-dose cardiac monitoring requirement and the postmarketing signals for PML, severe rebound disability after discontinuation, and pregnancy risk have shifted some prescribing toward newer S1P modulators with simpler initiation protocols.
Fingolimod has been studied in other inflammatory and autoimmune conditions but is not established for any indication outside MS. It should not be used outside its approved indication unless within an investigational protocol.
Dosing
Fingolimod is dosed once daily with or without food. Dosing is fixed by weight band in pediatric patients but otherwise does not require titration. The most clinically distinctive aspect of fingolimod administration is the mandatory 6-hour first-dose monitoring with ECG and hourly vital signs, required not only at the very first dose but also after dose increases (in pediatric patients moving from 0.25 mg to 0.5 mg) and after most treatment interruptions.
Standard Dosing
| Population | Recommended Dose | Notes |
|---|---|---|
| Adults and pediatric patients ≥10 years weighing >40 kg | 0.5 mg PO once daily | Take with or without food; doses higher than 0.5 mg are associated with more adverse reactions and no additional benefit |
| Pediatric patients ≥10 years weighing ≤40 kg | 0.25 mg PO once daily | If patient subsequently exceeds 40 kg and is switched to 0.5 mg, repeat first-dose 6-hour monitoring after the 0.5 mg dose Maximum dose: 0.5 mg/day |
First-Dose Monitoring (Required for All Patients)
Initiation of fingolimod transiently reduces heart rate and AV conduction. The decrease begins within 1 hour and reaches its nadir within 6 hours; a second period of heart rate decrease can occur up to 24 hours after the first dose. Monitoring is mandatory at: (a) the very first dose; (b) reinitiation after discontinuation longer than 14 days after the first month of therapy; and (c) when a pediatric patient on 0.25 mg switches to 0.5 mg. Within the first 2 weeks of therapy, repeat first-dose procedures are needed after any 1-day interruption; during weeks 3 and 4, after any interruption longer than 7 days.
| Time Point | Action |
|---|---|
| Pre-dose | Obtain ECG; verify no contraindication; review concomitant heart-rate-slowing or QT-prolonging drugs |
| 0–6 hours post-dose | Hourly pulse and blood pressure measurement; observe for symptoms of bradycardia (dizziness, fatigue, palpitations, chest pain) |
| End of 6 hours | Repeat ECG. Continue monitoring if any of: HR <45 bpm in adults / <55 bpm in patients ≥12 years / <60 bpm in patients 10–11 years; HR at lowest postdose value (suggesting nadir not yet reached); new second-degree or higher AV block on ECG. |
| If symptomatic bradycardia | Initiate continuous ECG monitoring; treat as appropriate; if pharmacological intervention required, observe overnight and repeat 6-hour monitoring after the second dose. |
| Overnight monitoring required | Patients with: pre-existing cardiac/cerebrovascular disease, prolonged QTc (>450 ms men / >470 ms women), additional QT risk factors, concomitant QT-prolonging drugs with risk of TdP, or concomitant heart-rate-slowing drugs (β-blockers, diltiazem, verapamil, digoxin) |
Pre-Initiation Assessments
- Cardiac: ECG; assessment for pre-existing cardiac conditions and concomitant heart-rate-slowing drugs.
- Hematology: Recent CBC (within 6 months or after discontinuation of prior therapy).
- Hepatic: Serum ALT, AST, and total bilirubin (within 6 months).
- Ophthalmologic: Baseline fundus and macular evaluation.
- Dermatologic: Baseline skin examination prior to or shortly after initiation.
- Vaccination: Test for VZV antibodies; vaccinate antibody-negative patients and wait 1 month before initiating therapy. Bring pediatric patients up to date with all immunizations per current schedule.
- HPV vaccination: Consider before initiation given postmarketing reports of HPV-related disease.
Special Populations
| Population | Recommendation | Rationale |
|---|---|---|
| Renal impairment (any severity) | 0.5 mg dose appropriate; no formal adjustment | In severe impairment, fingolimod Cmax/AUC increase ~32%/43% and metabolites M2/M3 increase 3- to 13-fold; metabolite toxicity not fully characterized |
| Mild or moderate hepatic impairment | No dose adjustment needed | Fingolimod AUC increases by ~12% (mild) or ~44% (moderate) |
| Severe hepatic impairment (Child-Pugh C) | Close monitoring; fingolimod AUC approximately doubled | Higher risk of adverse reactions; half-life prolonged ~50% |
| Geriatric (≥65 years) | Use with caution; clinical experience limited | Greater frequency of decreased hepatic/renal function and concomitant disease |
| Pediatric patients <10 years | Not recommended | Safety and effectiveness not established |
| Pregnancy planning | Stop 2 months before planned conception | 2-month washout for elimination; pregnancy registry suggests increased birth defect risk |
Verify that the patient does not have any of the following before administering the first dose: MI, unstable angina, stroke, TIA, decompensated heart failure with hospitalization, or Class III/IV heart failure within the past 6 months; history or presence of Mobitz Type II 2nd-degree or 3rd-degree AV block or sick sinus syndrome (without functioning pacemaker); baseline QTc ≥500 msec; treatment with Class Ia (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics; or known hypersensitivity to fingolimod. Skipping this check is the single most common preventable error in fingolimod initiation.
Pharmacology
Mechanism of Action
Fingolimod is a prodrug that undergoes phosphorylation by sphingosine kinase to its active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a high-affinity modulator of sphingosine 1-phosphate (S1P) receptors, binding S1P1, S1P3, S1P4, and S1P5. Through functional antagonism of S1P1 on lymphocytes, fingolimod-phosphate prevents the egress of lymphocytes from secondary lymphoid organs, sequestering them in lymph nodes and reducing peripheral lymphocyte counts. The mechanism by which fingolimod produces therapeutic benefit in MS is not fully established but is thought to involve reduced lymphocyte trafficking into the central nervous system. Effects on additional S1P receptor subtypes — particularly S1P1 and S1P3 on cardiomyocytes and the cardiac conduction system — explain the transient first-dose reductions in heart rate and AV conduction.
Clinically, fingolimod produces a rapid and sustained reduction in absolute lymphocyte count, falling to approximately 60% of baseline within 4–6 hours after the first dose and reaching a nadir of approximately 30% of baseline (around 500 cells/mcL) within 2 weeks of daily dosing. Approximately 18% of treated patients have at least one ALC measurement <200 cells/mcL during therapy. After discontinuation, lymphocyte counts begin to recover within days and typically return to normal within 1–2 months as drug exposure declines.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability ~93%; Tmax 12–16 hours; food does not affect Cmax or AUC | May be taken without regard to meals; long Tmax means peak effects on heart rate occur within 6 hours but the second nadir can occur up to 24 hours after first dose |
| Distribution | Vd ~1200 ± 260 L; protein binding >99.7%; ~86% distributed to red blood cells | Extensive tissue distribution; not removed by dialysis or plasma exchange |
| Metabolism | Reversible stereoselective phosphorylation by sphingosine kinase to fingolimod-phosphate (active); oxidative metabolism mainly by CYP4F2 (and possibly other CYP4F isozymes); pharmacologically inactive ceramide analogs also formed. Strong CYP3A4 induction may contribute to metabolism. | Inhibitors or inducers of CYP4F2 may alter exposure; minimal CYP3A4-mediated interactions at therapeutic doses |
| Steady State | Reached within 1–2 months of once-daily dosing; steady-state levels are approximately 10× the initial dose | Loading is not needed; full pharmacodynamic effect develops over weeks; missed doses early in therapy require repeat first-dose monitoring |
| Elimination | Mean blood clearance 6.3 ± 2.3 L/h; terminal half-life 6–9 days for both fingolimod and fingolimod-phosphate. ~81% excreted in urine as inactive metabolites; <2.5% in feces as parent or fingolimod-phosphate | Long half-life means pharmacodynamic effects (including lymphopenia) persist for ~2 months after discontinuation — pregnancy planning, vaccination, and switching to other immunomodulators all require this consideration |
Fingolimod and fingolimod-phosphate are not clinically meaningful inhibitors or inducers of major CYP isoenzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5) or P-glycoprotein at therapeutic concentrations. As a result, fingolimod is unlikely to alter the clearance of comedications metabolized by these pathways. Therapeutic drug monitoring is not used.
Side Effects
Adverse-event data below derive from the placebo-controlled adult Phase III studies (Studies 1 and 3 in the PI; FREEDOMS and FREEDOMS II), in which 783 patients received fingolimod 0.5 mg and 773 received placebo. Frequencies are fingolimod 0.5 mg followed by placebo. Pediatric safety in PARADIGMS was generally similar to adults except for a notably higher rate of seizures (5.6% vs 0.9% on intramuscular interferon beta-1a).
| Adverse Effect | Incidence (Fingolimod vs Placebo) | Clinical Note |
|---|---|---|
| Headache | 25% vs 24% | Modest increase over placebo; usually mild |
| Liver transaminase elevations (ALT/AST/GGT) | 15% vs 4% | Most appear within first 6–9 months; ≥3× ULN in 14% vs 3%; ≥5× ULN in 4.5% vs 1% |
| Diarrhea | 13% vs 10% | Generally mild and self-limited |
| Nausea | 13% vs 12% | Modest increase |
| Cough | 12% vs 11% | Component of mild respiratory effects |
| Influenza | 11% vs 8% | Annual inactivated influenza vaccination is recommended; live attenuated influenza vaccine should be avoided |
| Sinusitis | 11% vs 8% | Standard management |
| Abdominal pain | 11% vs 10% | Modest increase |
| Back pain | 10% vs 9% | Modest increase |
| Pain in extremity | 10% vs 7% | — |
| Adverse Effect | Incidence (Fingolimod vs Placebo) | Clinical Note |
|---|---|---|
| Dyspnea | 9% vs 7% | Reflects mild reductions in FEV1 and DLCO that may occur on therapy |
| Hypertension | 8% vs 4% | Mean increases of ~3 mmHg systolic and ~2 mmHg diastolic; appears around month 1 and persists; updated W&P 8/2025 emphasizes BP monitoring in adults and pediatric patients |
| Bronchitis | 8% vs 5% | Standard management |
| Lymphopenia (laboratory) | 7% vs <1% | Refers to the AE term; ALC reduces to ~30% of baseline within 2 weeks pharmacodynamically; ~18% of patients reach ALC <200 cells/mcL at least once |
| Migraine | 6% vs 4% | — |
| Vision blurred | 4% vs 2% | Investigate for macular edema if persistent or new |
| Bradycardia (during therapy) | 3% vs 1% | Beyond the first-dose effect; symptomatic first-dose bradycardia occurred in 0.6% on fingolimod vs 0.1% on placebo |
| Skin papilloma | 3% vs 2% | Periodic skin examinations recommended |
| Alopecia | 3% vs 2% | Usually mild and reversible |
| Blood triglycerides increased | 3% vs 1% | — |
| Basal cell carcinoma | 2% vs 1% | Skin examinations before/shortly after initiation and periodically thereafter |
| Herpes zoster | 2% vs 1% | VZV vaccination of antibody-negative patients before initiation; consider recombinant zoster vaccine per local guidelines |
| Tinea versicolor | 2% vs <1% | — |
| Actinic keratosis | 2% vs 1% | Increased UV protection counselling |
| Leukopenia (laboratory) | 2% vs <1% | Mild neutrophil reduction with chronic therapy |
| Asthenia | 2% vs 1% | Modest increase |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| First-dose symptomatic bradyarrhythmia and AV block | Symptomatic bradycardia 0.6% vs 0.1%; first-degree AV block 4.7% vs 1.6%; second-degree AV block (Mobitz I or 2:1) 4% vs 2%; postmarketing reports of third-degree AV block, transient asystole, and unexplained death | First 6 hours after first dose; rare events up to 24 hours | Mandatory 6-hour first-dose monitoring with ECG before/after; continue monitoring or admit overnight per criteria; high-risk patients require overnight continuous ECG |
| Serious infections (life-threatening or fatal) | Trial-period serious infection rate 2.3% vs 1.6% placebo; rates of bronchitis, herpes zoster, influenza, sinusitis and pneumonia increased | Throughout therapy and up to 2 months after discontinuation | Suspend therapy in serious infection; do not start in active infection; complete VZV vaccination antibody-negative patients before initiation |
| Disseminated herpetic infections (varicella zoster, herpes simplex including encephalitis) | Postmarketing — frequency not established; multiorgan failure reported | Variable | Include in differential of atypical relapse or multiorgan failure; treat aggressively; consider withholding fingolimod |
| Cryptococcal infections (including meningitis) | Postmarketing — fatal cases reported; typically after ~2 years of therapy but may occur earlier | Generally after ~2 years | Prompt diagnostic evaluation and treatment in patients with consistent symptoms (headache, fever, altered mental status) |
| Progressive multifocal leukoencephalopathy (PML) | Postmarketing — has occurred in patients without prior natalizumab exposure; majority of cases after ≥18 months of therapy | Months to years; risk increases with longer therapy | Withhold fingolimod at first sign or symptom suggestive of PML; obtain MRI and CSF JCV PCR; if confirmed, discontinue; monitor for IRIS after stopping |
| Macular edema | 0.5% on 0.5 mg vs 0.4% placebo; ~20% in patients with history of uveitis vs 0.6% without; also increased in diabetes | Predominantly in first 3–4 months | Baseline fundus and macular exam; repeat at 3–4 months and periodically; any change in vision warrants urgent ophthalmologic review; consider discontinuation if macular edema develops |
| Liver injury (clinically significant) | ≥3× ULN ALT/AST/GGT in 14% vs 3%; ≥5× ULN in 4.5% vs 1%; postmarketing acute liver failure requiring liver transplant | Most enzyme elevations within 6–9 months; injury reported as early as 10 days | Baseline ALT/AST/total bilirubin; monitor periodically and through 2 months after stopping; interrupt if ALT >3× and bilirubin >2× ULN without alternative cause; do not resume if no other etiology found |
| Posterior reversible encephalopathy syndrome (PRES) | Rare; reported in adult patients on fingolimod | Variable | Discontinue fingolimod if PRES suspected (severe headache, altered mental status, visual disturbances, seizure); delay in treatment can lead to permanent sequelae |
| Severe increase in disability after discontinuation | Postmarketing — multiple new MRI lesions and severe disability rebound; most patients did not return to pre-stop functional status | Generally within 12 weeks of stopping; reported up to 24 weeks | Counsel patients not to discontinue without specialist input; monitor closely after planned discontinuation; consider bridging therapy when possible, especially if stopping for pregnancy |
| Tumefactive multiple sclerosis | Postmarketing — most cases within first 9 months of fingolimod or first 4 months after discontinuation | First 9 months on therapy or shortly after stopping | Consider in any severe MS relapse during or after fingolimod; obtain imaging and treat appropriately |
| Cutaneous malignancies (BCC, melanoma; squamous cell, Merkel cell, Kaposi’s reported postmarketing) | BCC 2% vs 1% in trials; melanoma reported postmarketing | Variable | Skin examination before or shortly after initiation and periodically; promptly evaluate suspicious lesions; counsel sun protection; avoid concomitant UV-B or PUVA phototherapy |
| Lymphoma (T-cell, B-cell, CNS lymphoma; cutaneous T-cell lymphoma reported) | Postmarketing — non-Hodgkin lymphoma reporting rate exceeds expected adjusted general population rate | Variable | Maintain clinical vigilance; investigate persistent lymphadenopathy or B-symptoms |
| Hypersensitivity reactions (rash, urticaria, angioedema) | Postmarketing — frequency not established | After initiation | Discontinue and treat as for hypersensitivity reaction; do not rechallenge |
| Seizures (including status epilepticus) | Adult trials 0.9% vs 0.3% placebo; pediatric trial 5.6% vs 0.9% on IFN beta-1a | Variable; pediatric incidence higher | Consider in differential of new neurological events; particular vigilance in pediatric patients |
| Hemolytic anemia and thrombocytopenia | Postmarketing — frequency not established | Variable | Investigate unexplained anemia or low platelets; consider discontinuation |
One of the most important fingolimod-specific safety signals is the risk of severe rebound MS disability after discontinuation, characterized by multiple new MRI lesions and clinical worsening that often does not return to the pre-stop functional baseline. Most reported cases occurred within 12 weeks of stopping, with reports up to 24 weeks. This risk is particularly relevant when stopping for pregnancy planning (the 2-month washout window), switching to a different DMT, or interruption for adverse events. Discuss bridging strategies with the MS specialist before any planned interruption.
Drug Interactions
Fingolimod has clinically meaningful interactions with three categories of drugs: those that prolong QT or slow heart rate (additive cardiac risk at initiation), those that affect CYP4F2/CYP3A4 metabolism (altered fingolimod exposure), and other immunomodulating or immunosuppressive therapies (additive immune effects). Live vaccines must be avoided during therapy and for 2 months after discontinuation.
Monitoring
Fingolimod requires structured baseline assessments and ongoing surveillance for cardiac, hematologic, hepatic, ophthalmic, dermatologic, and infectious complications. The intensity of monitoring is greatest at initiation but persists throughout therapy and for at least 2 months after discontinuation because of the long pharmacodynamic tail.
-
Cardiac (ECG, vital signs)
Pre-dose and end of 6-hour observation; 6-hour first-dose monitoring with hourly pulse and BP. Repeat after >14-day interruption (and shorter interruptions in first 4 weeks per protocol) and dose increases
Routine Continue monitoring beyond 6 hours if HR <45 bpm (adults), <55 bpm (≥12 yr), <60 bpm (10–11 yr); HR at lowest postdose value; new ≥2nd-degree AV block. Overnight continuous ECG required for high-risk patients (cardiac history, QTc >450 ms men/>470 ms women, QT-prolonging drugs, rate-slowing drugs). -
Complete blood count (CBC) with lymphocyte count
Within 6 months before initiation; periodically during therapy and as clinically indicated
Routine Note that absolute lymphocyte count cannot be used to evaluate lymphocyte subsets on therapy because of redistribution into lymphoid tissue. ALC will normally drop to ~30% of baseline within 2 weeks. Evaluate persistent very low ALC (especially <200 cells/mcL) for serious infection risk. -
Liver function (ALT, AST, total bilirubin)
Within 6 months before initiation; periodically during therapy and through 2 months after discontinuation
Routine Most enzyme elevations occur within 6–9 months. Interrupt therapy if ALT >3× ULN with bilirubin >2× ULN; do not resume if no alternative cause is identified. -
Ophthalmologic examination (fundus, including macula)
Baseline; 3–4 months after initiation; periodically during therapy; immediately for any vision change
Routine Patients with diabetes mellitus or history of uveitis are at substantially increased risk and require regular follow-up examinations. OCT can detect subclinical macular edema. -
Skin examination
Baseline (prior to or shortly after initiation); periodically thereafter; promptly evaluate any suspicious lesion
Routine Increased risk of basal cell carcinoma, squamous cell carcinoma, melanoma, Merkel cell carcinoma, and Kaposi’s sarcoma. Counsel sun protection and avoid concomitant UV-B or PUVA phototherapy. -
Blood pressure
During treatment in adults and pediatric patients (warning emphasized 8/2025)
Routine Mean increases of ~3 mmHg systolic and ~2 mmHg diastolic emerge in the first month and persist; manage per standard hypertension guidelines. -
Symptoms of infection (including PML)
At each clinical contact during therapy and for 2 months after discontinuation
Routine Vigilance for HSV/VZV (including disseminated zoster and zoster ophthalmicus), cryptococcal infection (especially after ~2 years on therapy), and PML (any new progressive neurological deficit, especially after ≥18 months of therapy). -
Pregnancy testing
Before initiation in females of reproductive potential; effective contraception during treatment and for 2 months after stopping
Routine Plan stopping of fingolimod 2 months before planned conception; balance against risk of severe disability rebound. -
VZV antibody status
Before initiation in patients without documented chickenpox or VZV vaccination
Trigger-based Vaccinate antibody-negative patients and delay fingolimod by 1 month after the second dose. -
Pulmonary function
Spirometry (FEV1) and DLCO when clinically indicated (e.g., new or worsening dyspnea)
Trigger-based Mild reductions in FEV1 and DLCO are expected; investigate persistent or symptomatic decline. -
MRI of brain
Per MS practice for disease monitoring; urgently for suspected PML, tumefactive MS, or rebound disability after stopping
Trigger-based MRI may detect PML lesions before clinical symptoms; differentiate carefully from MS relapse, especially after long therapy or at discontinuation. -
Cervical cancer screening (Pap test)
Per local guidelines for immunosuppressed patients
Trigger-based Postmarketing reports of HPV-related dysplasia and cancer; consider HPV vaccination before initiation.
The most commonly missed monitoring requirement in clinical practice is repeat first-dose monitoring after a treatment interruption. Within the first 2 weeks of therapy, any 1-day interruption requires repeat 6-hour monitoring. During weeks 3 and 4, an interruption of more than 7 days requires repeat. After the first month, interruptions longer than 14 days require repeat first-dose monitoring. Pediatric patients moving from 0.25 mg to 0.5 mg also require monitoring with the new dose. When in doubt, repeat the protocol — the clinical risk of cardiac events on reinitiation is real, even in patients who tolerated the original first dose without incident.
Contraindications & Cautions
Absolute Contraindications
- Recent (within 6 months) MI, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or NYHA Class III/IV heart failure.
- History or presence of Mobitz Type II 2nd-degree or 3rd-degree AV block, or sick sinus syndrome (unless the patient has a functioning pacemaker).
- Baseline QTc interval ≥500 msec.
- Cardiac arrhythmias requiring treatment with Class Ia (e.g., quinidine, procainamide, disopyramide) or Class III (e.g., amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic drugs.
- Known hypersensitivity to fingolimod or any excipient (reactions reported include rash, urticaria, and angioedema upon initiation).
Relative Contraindications — Specialist Input Recommended
- Active acute or chronic infection, especially serious bacterial, viral, fungal, or opportunistic infection — defer until resolved.
- Pre-existing severe lymphopenia.
- Active or suspected progressive multifocal leukoencephalopathy.
- Severe untreated sleep apnea, recurrent syncope, history of symptomatic bradycardia, or other cardiovascular risk factors — overnight monitoring required if therapy proceeds.
- Severe active hepatic disease (Child-Pugh C requires close monitoring; suspected drug-induced liver injury attributable to fingolimod is reason to discontinue).
- Concomitant treatment with QT-prolonging drugs at high risk of torsades de pointes — overnight ECG monitoring required.
- Concomitant treatment with heart-rate-slowing drugs (β-blockers, digoxin, diltiazem, verapamil) — switch where feasible or use overnight monitoring.
- Concomitant immunosuppressive, immune-modulating, or antineoplastic therapy — additive risk of infection.
- Recent or planned use of live vaccines.
- Pregnancy or pregnancy planning — see Use in Specific Populations; stop 2 months before planned conception.
- Diabetes mellitus or history of uveitis — substantially elevated risk of macular edema; close ophthalmologic surveillance.
Use With Caution
- Patients with skin cancer history or strong family history — periodic skin examination, sun protection counselling.
- Patients with chronic respiratory disease — fingolimod produces small reductions in FEV1 and DLCO.
- Geriatric patients (≥65 years) — limited clinical experience; greater frequency of comorbidity.
- Pediatric patients <10 years — safety and effectiveness not established.
- Lactation — present in animal milk; effects on breastfed infant unknown.
- Patients on strong CYP enzyme inducers (e.g., carbamazepine, rifampicin, phenytoin, phenobarbital, St. John’s wort) — fingolimod exposure may be reduced.
- Patients on systemic ketoconazole — fingolimod exposure increases ~70%.
Bradyarrhythmia and AV blocks (5.1) — requires structured 6-hour first-dose monitoring with ECG; overnight monitoring for high-risk patients.
Serious and life-threatening infections (5.2) — including disseminated herpes, cryptococcal meningitis, HPV-related disease.
Progressive multifocal leukoencephalopathy (5.3) — risk increases after 18+ months of therapy; can occur in absence of prior natalizumab exposure.
Macular edema (5.4) — especially in diabetes and prior uveitis.
Liver injury (5.5) — including acute liver failure requiring transplant; monitor LFTs and through 2 months after stopping.
PRES (5.6), respiratory effects (5.7), fetal risk (5.8, updated 8/2025), severe disability rebound after stopping (5.9), tumefactive MS (5.10), increased blood pressure (5.11, updated 8/2025), cutaneous and lymphoid malignancies (5.12), persistent immune effects after discontinuation (5.13), and hypersensitivity (5.14).
Patient Counselling
Purpose of Therapy
Explain that fingolimod is a long-term once-daily oral medication used to reduce relapses and slow disability progression in relapsing forms of multiple sclerosis. It does not cure MS, but pivotal trials and long-term extension data show sustained reductions in relapse rate and brain MRI lesion activity compared with placebo or interferon beta-1a. The capsule should be swallowed whole and may be taken with or without food.
How to Take
The first dose must be given in a healthcare setting where the patient can be observed for at least 6 hours with regular pulse, blood pressure, and ECG monitoring. After the initial period, the medication is taken once daily at home. If a dose is missed early in therapy, contact the prescriber before resuming — the first-dose observation may need to be repeated. Do not stop fingolimod without first speaking with the prescribing clinician, because severe rebound MS activity has been reported after discontinuation.
Sources
- Novartis Pharmaceuticals Corporation. Gilenya (fingolimod) capsules — full prescribing information. Revised August 2025. Available via DailyMed at: https://dailymed.nlm.nih.gov/ Authoritative source for indication, weight-banded dosing, first-dose monitoring protocols, the five contraindications, the 14 Warnings and Precautions (including 8/2025 updates to fetal risk and increased blood pressure), the integrated adverse-reactions table, the pregnancy registry data through 2024, and pharmacokinetics.
- U.S. Food and Drug Administration. Fingolimod (marketed as Gilenya) Information. Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fingolimod-marketed-gilenya-information Postmarket safety updates and FDA Drug Safety Communications, including the communication on PML in patients without prior immunosuppressant exposure.
- Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. doi: 10.1056/NEJMoa0909494 (PMID: 20089952) Pivotal Phase III FREEDOMS trial demonstrating reductions in annualized relapse rate and disability progression versus placebo over 24 months; basis for FDA approval in adults.
- Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415. doi: 10.1056/NEJMoa0907839 (PMID: 20089954) Phase III TRANSFORMS trial demonstrating superiority of fingolimod 0.5 mg over intramuscular interferon beta-1a on annualized relapse rate over 12 months.
- Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545–556. doi: 10.1016/S1474-4422(14)70049-3 Confirmatory Phase III placebo-controlled trial reproducing the relapse-rate and MRI benefits seen in FREEDOMS in a North American–enriched population.
- Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018;379(11):1017–1027. doi: 10.1056/NEJMoa1800149 First randomized controlled trial of an MS disease-modifying therapy in pediatric patients; basis for the May 2018 FDA approval expansion to patients ≥10 years of age. Demonstrated 81.9% relative reduction in annualized relapse rate versus IM interferon beta-1a.
- Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–788. doi: 10.1212/WNL.0000000000005347 (Reaffirmed October 2024) AAN consensus practice guideline that situates fingolimod among MS disease-modifying therapies and addresses starting, switching, and stopping decisions, including post-discontinuation MRI surveillance.
- Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96–120. doi: 10.1177/1352458517751049 (PMID: 29353550) Joint European guideline on use of fingolimod and other DMTs, including monitoring frameworks for cardiac risk, lymphopenia, PML, and pregnancy.
- Kappos L, O’Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, Ritter S, Schlosshauer R, von Rosenstiel P, Zhang-Auberson L, Francis G. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015;84(15):1582–1591. doi: 10.1212/WNL.0000000000001462 (PMID: 25795646) Long-term extension data demonstrating sustained efficacy of fingolimod over multiple years and informing the long-term safety profile reflected in the current label.
- Cohen JA, Tenenbaum N, Bhatt A, Zhang Y, Kappos L. Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Ther Adv Neurol Disord. 2019;12:1756286419878324. doi: 10.1177/1756286419878324 Long-term safety and efficacy data over up to 14 years of fingolimod exposure across DEFINE/CONFIRM/ENDORSE-equivalent extension studies, supporting durable benefit-risk profile.